TG Therapeutics, Inc. (TGTX): Price and Financial Metrics


TG Therapeutics, Inc. (TGTX): $37.77

-0.20 (-0.53%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add TGTX to Watchlist
Sign Up

Industry: Biotech


Ranked

of 487

in industry

TGTX POWR Grades


  • TGTX scores best on the Value dimension, with a Value rank ahead of 39.3% of US stocks.
  • TGTX's strongest trending metric is Momentum; it's been moving down over the last 31 weeks.
  • TGTX ranks lowest in Momentum; there it ranks in the 9th percentile.

TGTX Stock Summary

  • Tg Therapeutics Inc's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than only 7.78% of US listed stocks.
  • TGTX's price/sales ratio is 5,485.6; that's higher than the P/S ratio of 99.66% of US stocks.
  • Revenue growth over the past 12 months for Tg Therapeutics Inc comes in at 496.71%, a number that bests 98.51% of the US stocks we're tracking.
  • Stocks that are quantitatively similar to TGTX, based on their financial statements, market capitalization, and price volatility, are VHC, CVM, VNRX, CRSP, and AQMS.
  • TGTX's SEC filings can be seen here. And to visit Tg Therapeutics Inc's official web site, go to www.tgtherapeutics.com.

TGTX Price Target

For more insight on analysts targets of TGTX, see our TGTX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $75.33 Average Broker Recommendation 1.36 (Strong Buy)

TGTX Stock Price Chart Interactive Chart >

Price chart for TGTX

TGTX Price/Volume Stats

Current price $37.77 52-week high $56.74
Prev. close $37.97 52-week low $16.56
Day low $37.22 Volume 863,400
Day high $38.12 Avg. volume 1,475,503
50-day MA $39.57 Dividend yield N/A
200-day MA $38.50 Market Cap 5.34B

TG Therapeutics, Inc. (TGTX) Company Bio


TG Therapeutics is a biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. The company was founded in 1993 and is based in New York, New York.


TGTX Latest News Stream


Event/Time News Detail
Loading, please wait...

TGTX Latest Social Stream


Loading social stream, please wait...

View Full TGTX Social Stream

Latest TGTX News From Around the Web

Below are the latest news stories about Tg Therapeutics Inc that investors may wish to consider to help them evaluate TGTX as an investment opportunity.

TG Therapeutics Announces Data Presentations at the Upcoming 16th International Congress on Malignant Lymphoma

NEW YORK, June 09, 2021 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule of upcoming data presentations at the 16th International Congress on Malignant Lymphoma (ICML), being held virtually June 18 – 22, 2021. Details of the data presentations are included below. Poster Presentation Title: TG-1701, A Selective Bruton Tyrosine Kinase (BTK) Inhibitor, as Monotherapy and in Combination with Ublituximab and Umbralisib (U2) in Patients with B-cell Malignancies Ab

Yahoo | June 9, 2021

TG Therapeutics Announces Data from a Phase 1 Study Evaluating TG-1701 as a Monotherapy and as a Triple Combination with Ublituximab and UKONIQ® at the 2021 American Society of Clinical Oncology Annual Meeting

100% ORR in CLL patients treated with 300 mg QD of TG-1701 monotherapy (n=19) Triple combination of ublituximab and UKONIQ (U2) + TG-1701 cohort (n=19) resulted in 79% ORR, with 21% CR rate, including 100% ORR in patients WM, CLL, MZL, MCL, and DLBCL (n=11) NEW YORK, June 04, 2021 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced data from TG-1701, the Company’s investigational once-daily, oral BTK inhibitor, as a monotherapy and as a triple therapy in combination with ub

Yahoo | June 4, 2021

TG Therapeutics' Ublituximab-Umbralisib Combo Application Under FDA Review for Hematological Malignancies

The FDA has accepted for review TG Therapeutics Inc's (NASDAQ: TGTX ) marketing application seeking approval for ublituximab in combination with Ukoniq (umbralisib) for chronic lymphocytic leukemia … Full story available on Benzinga.com

Benzinga | May 25, 2021

TG Therapeutics Announces FDA Acceptance of Biologics License Application for Ublituximab in Combination with UKONIQ® (umbralisib) as a Treatment for Patients with Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

Prescription Drug User Fee Act (PDUFA) goal date of March 25, 2022NEW YORK, May 25, 2021 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that the U.S. Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for ublituximab, the Company’s investigational glycoengineered anti-CD20 monoclonal antibody, in combination with UKONIQ® (umbralisib), the Company’s once-daily, oral, inhibitor of PI3K-delta and CK1-epsilon, as a treatment for patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). The FDA has set a Prescription Drug User Fee Act (PDUFA) goal date of March 25, 2022. The FDA also notified the Company that it is not currently planning to hold an advisory committee meeting to discuss this applicati...

Yahoo | May 25, 2021

TG Therapeutics Announces Data Presentations at Upcoming Medical Meetings

NEW YORK, May 13, 2021 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule of upcoming data presentations at the American Society of Clinical Oncology (ASCO) annual meeting, to be held virtually June 4 – 8, 2021 and the European Hematology Association (EHA) annual congress, to be held virtually June 9 – 17, 2021. Details of the data presentations are included below. Michael S. Weiss, the Company’s Executive Chairman and Chief Executive Officer stated, “We are excited to share updated data for TG-1701, our novel BTK inhibitor, as a monotherapy, and as a triple therapy with U2, at the upcoming ASCO and EHA annual congresses. The EHA abstract released yesterday included an update from the data most recently presented at the ASH 2020 congress, and we are p...

Yahoo | May 13, 2021

Read More 'TGTX' Stories Here

TGTX Price Returns

1-mo 10.25%
3-mo -21.48%
6-mo -26.19%
1-year 119.72%
3-year 174.69%
5-year 439.57%
YTD -27.39%
2020 368.65%
2019 170.73%
2018 -50.00%
2017 76.34%
2016 -61.02%

Continue Researching TGTX

Want to see what other sources are saying about Tg Therapeutics Inc's financials and stock price? Try the links below:

Tg Therapeutics Inc (TGTX) Stock Price | Nasdaq
Tg Therapeutics Inc (TGTX) Stock Quote, History and News - Yahoo Finance
Tg Therapeutics Inc (TGTX) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.8381 seconds.